RBC Capital: 'Moonlake Immunotherapeutics (MLTX) Remains A Top Catalyst-Driven Idea'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $67.00 price target on Moonlake Immunotherapeutics (NASDAQ: MLTX).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
